Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verteporfin + pembrolizumab + fluorouracil + irinotecan + leucovorin + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination treatment approach, evaluated in a Phase II clinical trial at Mayo Clinic, integrates photodynamic priming (PDP) with immunotherapy and chemotherapy for patients with unresectable, locally advanced, or metastatic pancreatic cancer. The regimen consists of the photosensitizer verteporfin (Visudyne), the PD-1 inhibitor pembrolizumab (Keytruda), and the chemotherapy combination mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin). Verteporfin is administered intravenously and subsequently activated by intratumoral laser light (690 nm) delivered via endoscopic ultrasound or CT guidance. This activation generates cytotoxic reactive oxygen species that induce localized tumor necrosis and are hypothesized to prime the tumor microenvironment, thereby enhancing the efficacy of the pembrolizumab-mediated immune response against pancreatic ductal adenocarcinoma.
- Other names
- Photodynamic Priming and Pembrolizumab in Pancreatic CancerPDP + pembrolizumab + mFOLFIRINOX
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)
Beyond the preview
Go deeper on verteporfin + pembrolizumab + fluorouracil + irinotecan + leucovorin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verteporfin + pembrolizumab + fluorouracil + irinotecan + leucovorin + oxaliplatin.